Glipizide Extended-Release Tablets and Synalar (Fluocinolone Solution)
Determining the interaction of Glipizide Extended-Release Tablets and Synalar (Fluocinolone Solution) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration. Use of occlusive dressings over the applied areas may also increase percutaneous absorption. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.
- "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
- Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7
- Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42
- "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
- Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
- "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
- Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
- "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
Generic Name: glipizide
Brand name: Glucotrol, Glucotrol XL, Glipizide XL
Synonyms: Glipizide, GlipiZIDE
Generic Name: fluocinolone topical
Brand name: Capex, Flurosyn, Synalar, Synalar Ointment, Derma-Smoothe/FS
Synonyms: Synalar
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Glipizide Extended-Release Tablets-Synalar Mild
- Glipizide Extended-Release Tablets-Synalar Ointment
- Glipizide Extended-Release Tablets-Synalar Regular
- Glipizide Extended-Release Tablets-Synalar Solution
- Glipizide Extended-Release Tablets-Synalgos-DC
- Glipizide Extended-Release Tablets-Synalgos-DC Oral
- Synalar (Fluocinolone Solution)-Glipizide Tablets
- Synalar (Fluocinolone Solution)-Glipizide XL
- Synalar (Fluocinolone Solution)-Glofil-125
- Synalar (Fluocinolone Solution)-Gloperba
- Synalar (Fluocinolone Solution)-GloStrips
- Synalar (Fluocinolone Solution)-Glucagen